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Abstract  
Purpose: Methods used to deliver and test a pharmacy-based asthma care telephonic service for an underserved, rural patient 
population are described.   
Summary: In a randomized controlled trial (RCT), the Patient And phaRmacist Telephonic Encounters (PARTE) project is assessing the 
feasibility, acceptability, and preliminary impact of providing pharmacy-based asthma care service telephonically. The target 
audience is a low income patient population across a large geographic area served by a federally qualified community health center.  
Ninety-eight participants have been randomized to either standard care or the intervention group who received consultation and 
direct feedback from pharmacists via telephone regarding their asthma self-management and medication use. Pharmacists used a 
counseling framework that incorporates the Indian Health Services 3 Prime Questions and the RIM Technique (Recognition, 
Identification, and Management) for managing medication use problems. Pharmacists encouraged patients to be active partners in 
the decision-making process to identify and address the underlying cause of medication use problems.  Uniquely, this trial collected 
process and summative data using qualitative and quantitative approaches. Pharmacists’ training, the fidelity and quality of 
pharmacists’ service delivery, and short term patient outcomes are being evaluated. This evaluation will improve our ability to 
address research challenges and intervention barriers, refine staff training, explore patient perspectives, and evaluate measures’ 
power to provide preliminary patient outcome findings. 
Conclusion:  A mixed method evaluation of a structured pharmacist intervention has the potential to offer insights regarding staff 
training, service fidelity and short term outcomes using quantitative and qualitative data in an RCT.  Results will provide evidence 
regarding the feasibility and quality of carrying out the study and service delivery from the multiple perspectives of participants, 
clinicians, and researchers.  
  
 
Introduction 
Asthma is a prevalent and costly long-term condition that can 
be associated with diminished quality of life, morbidity and 
mortality.
1-11
  Over 24 million American adults, or 8.2% of the 
US population, had a diagnosis of asthma in 2009.
12
  In 
addition, individuals with family incomes below the federal 
poverty level have higher prevalence of asthma than those at 
or above the poverty level.
12
  The prevalence of lifetime  
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asthma is increasing at a similar rate among urban and rural 
populations in the US, but it is a particular problem for rural 
residents of some states.
13
  The cost associated with caring 
for people with asthma in the US is approximately $20.7 
billion, $5.6 billion of which is accounted for by prescription 
drugs.
1
  
 
Optimal medication use, which is part of asthma patient self-
management, is a vital strategy to improve asthma control.
14
  
Although appropriate use of prescription medications 
prevents exacerbations and improves patients’ quality of life, 
many patients have difficulties adhering to regimens.
15,16
  
Common asthma medication use problems include under-
utilization of controller medications, overuse of rescue 
medications and improper inhaler technique and are 
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associated with inadequate asthma control, poor quality of 
life, and increased emergency and non-emergency health 
services utilization.
17,18
  Patients’ non-adherence to asthma 
medication regimens range from 30% to 80%.
17
  Factors 
contributing to patients’ non-adherence with asthma 
medication therapy can include regimen complexity, difficulty 
with self-monitoring, difficulty with the routes of drug 
delivery and mastery of needed skills, lack of patient 
education and understanding of techniques and goals, and an 
underestimated disease severity.
16
   
 
Pharmacists are uniquely positioned in the health care system 
to efficiently intervene with and help patients overcome 
barriers to appropriate medication use.
19-21
  Pharmacists can 
provide patient education and monitor medication use to 
prevent or solve drug therapy problems.
14,22-24
  Pharmacist 
care services have successfully improved health outcomes 
and have been positively associated with patient 
satisfaction.
14,22,24
  Pharmacy-based programs can improve 
asthma outcomes; however less data are available regarding 
their impact on rural populations in the US.
14,24,25
 
 
Rural patients have problematic access to health care services 
including programs that could improve their medication use 
and asthma control, due to economic and supply 
disparities.
26,27
  Data, although limited, also suggest that 
patients living in rural areas receive inferior care for their 
asthma.
26,28
  Whereas studies support the use of pharmacy-
based services to aid patients’ asthma care, rural pharmacy 
practices face recruitment, retention, and workload pressures 
that may impact their ability to provide patient care 
services.
29
   Rural patients need novel ways of asthma care 
delivery.  Telemedicine (e.g., telephone, televideo) could 
provide instrumental opportunities.
30
 
 
The provision of pharmacist care through the use of 
telecommunications and information technologies to patients 
at a distance (e.g., telepharmacy), has offered promise in 
improving patients’ access to health care services.
31
  
International research has shown that it is feasible and cost-
effective to conduct pharmacist-based patient care services 
using telemedicine.
32,33
  In addition, Bynum et al found that 
patient education provided by pharmacists via interactive 
compressed video was an effective method for teaching and 
improving metered-dose inhaler technique in a rural, 
adolescent US population.
34
  However, to the best of our 
knowledge, there are no published evaluations of pharmacist-
based care for underserved, rural patients with asthma via 
telephonic interaction in the US.   
 
Evaluating the feasibility and outcomes of telepharmacy 
services for low income, rural populations are particularly 
important for patients with limited access to care.  If 
successful, the results have implications for transferability to 
other high need populations and medical conditions.  In this 
paper, we discuss methodology used to pilot-test a 
pharmacy-based asthma care service for an underserved, 
rural patient population.  Our intention is to offer a model 
that others can consider for future pilot pharmacy service 
delivery programs. 
 
Study Design 
The Patient And phaRmacist Telephonic Encounters (PARTE) 
project was designed to assess the feasibility, acceptability, 
and preliminary impact of providing pharmacy-based asthma 
care telephonically to an underserved, rural patient 
population using a randomized controlled design.  
Participants randomized to the intervention group receive 
consultation and direct feedback from pharmacists via 
telephone regarding their asthma self-management and 
medication use (as described below).  Five clinic-based 
pharmacists perform the intervention.  The intervention is 
incorporated into the usual practice and daily activities of the 
pharmacists.  Participants randomized to the control group 
receive usual care, consisting of the receipt of written 
medication use instructions through the mail with a 
prescription. Pre- and post-intervention telephone surveys 
are conducted by an interviewer.  Telephone interviews with 
study participants are conducted to explore facilitators and 
barriers associated with implementing the intervention. Five 
trained pharmacists are conducting the program.  The study 
was approved by the Marshfield Clinic Institutional Review 
Board and the Health Sciences Institutional Review Board at 
the University of Wisconsin Madison.   
 
Participants   
The study involves patients who are served by Family Health 
Center of Marshfield, Inc. (FHC), a federally funded 
community health center that partners with Marshfield Clinic 
(MC) to provide services to low income patients.  Marshfield 
Clinic is a multispecialty, non-profit, 501(c)(3) organization, 
employing over 775 physicians in 80 medical specialties and 
subspecialties providing care in over 50 locations throughout 
northern, central and western Wisconsin.  FHC patients 
receive pharmacy services primarily through the in-house 
340B pharmacy that provides mail-order services at no 
patient copayment or out of pocket costs.  Currently, the FHC 
pharmacy provides care for approximately 1000 patients with 
asthma, dispensing an estimated 3000 asthma medications in 
2009.   
 
The FHC service area is 8228 square miles and is located 
within an eleven county region in north central Wisconsin.  
This predominantly rural area is comprised of 254 
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municipalities, 78% of which are populated by less than 1000 
people. Within this service area, all individuals living at or 
below 200% of the federal poverty level who experience 
barriers to health and dental services are eligible to apply for 
FHC care.  Eighty-six percent of the service area population 
resides in communities that have been designated by the 
federal government as medically underserved areas and/or a 
medical, dental, or mental health professional shortage area.  
The region is 97% White, with a small but growing Hispanic 
population. 
 
Study participants were identified from electronic health 
records (medical and pharmacy).  Patients are included if they 
are: English speaking; ≥ 19 years of age; have a confirmed 
asthma diagnosis; receive ≥ 1 asthma medications dispensed 
via mail-order from FHC pharmacy in the 6 month period 
ending January 31, 2009; and documented to have a 
medication possession ratio of less than 80% or over 120% 
for asthma controller medications.  Patients are excluded 
from the study if they participate in an automatic refill 
program, have chronic obstructive pulmonary disease 
(COPD), or participate in any other asthma management 
programs.     
 
Recruitment and Randomization 
Because of the pilot nature of this study, our goal was to 
recruit 100 participants.  Eligible study participants were 
mailed a letter on Marshfield Clinic Research Foundation 
letterhead to introduce them to the study. The mailings 
included additional information sheets describing the study 
and consent forms without signature requirements.  
 
Approximately 4-5 days following this mailing, an experienced 
interviewer contacted prospective study participants to 
determine their willingness to enroll in the study and 
answered any questions they have about the study. The 
interviewer also screened prospective participants for 
remaining study exclusion criteria (i.e., participation in any 
medication auto-refill programs). If an individual was 
interested, the interviewer obtained oral consent and 
conducted a pre-intervention survey to assess asthma 
control, self-reported adherence, patient activation, and 
satisfaction with pharmacy services.   
 
A rolling, 3-month study enrollment period was conducted.  
After participants were recruited and the pre-survey 
completed, their information was forwarded to a data 
coordinator.  The data coordinator randomly assigned half of 
the participants to each group.  We used a block 
randomization scheme, specifying the number of and 
randomly allocating participants to each group, to balance 
the group sizes and reduce bias and confounding.
35
    Because 
this is a pilot study, participants were not stratified based on 
asthma severity or other medical conditions.  The data 
coordinator then forwarded a list of intervention participants 
(along with contact information) to the study pharmacists for 
further contact. Thus, the interviewers and study pharmacists 
were blinded to the randomization of participants to the 
intervention and control groups. 
 
Approximately 3 months after the final pharmacists' 
telephone contact, interviewers re-contacted all study 
participants and conducted a post-intervention telephone 
survey (outcome evaluation).  The control group was 
contacted during this same time period.  At the end of the 
post-intervention survey, 15 intervention group participants 
were randomly invited to participate in a follow-up interview 
(process evaluation).  In addition, participants are reimbursed 
$75 for study participation: $50 at the beginning and $25 for 
study completion. 
 
Control Group 
The control group continued to receive their asthma 
medications and support from their FHC pharmacists as per 
the current standard of service. The current service provided 
to all FHC patients managing their asthma is as follows: 1) 
medication refills are mailed to the patient’s home upon their 
request, 2) the FHC pharmacist provides additional education 
and pharmaceutical care services at the patient’s request, 3) 
the FHC patients are given a toll-free number to call their 
pharmacist if they have questions; this information is 
provided in each mailed prescription and in quarterly 
newsletters, and 4) medication information (both FDA 
required and standard medication guides) for each 
prescription is provided with each dispensing.  Other avenues 
of contact available to control group receiving usual care can 
include interactions when phoning in a prescription order, 
seeking clarification on written materials and when picking up 
an acute care medication at one of the other affiliated 
program pharmacies or another community pharmacy 
outside of the FHC program. 
 
Intervention 
The intervention group had three telephone contacts with 
study pharmacists spaced at approximately 4-week intervals 
during the first 13 weeks of their study enrollment.  During 
the telephone contacts, study pharmacists used a scripted 
communication guide to assess patients’ current use of and 
potential barriers with asthma medications.   The 
communication guide focuses on three areas based on the 
Indian Health Services’ (IHS) patient-counseling model: 
purpose of the prescribed medications, directions for using 
the medications, and monitoring for efficacy and side 
effects.
36
  The RIM Technique for managing medication use 
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problems also was used to shape pharmacists’ interactions 
with participants.  The RIM Technique contains the following 
three steps: 1) Recognition – assess the presence of a 
medication use problem, 2) Identification – determine the 
root cause of the medication use problem, and 3) 
Management – develop a plan, with the patient as an active 
partner in the decision-making process, to address the 
underlying cause and resolution of the medication use 
problem.      
 
Following a concordance perspective, pharmacists 
collaborated with participants to identify root cause(s) and 
implement solutions to resolve medication use problems.
37
  
The root cause(s) of medication use problems include 
knowledge (misconception regarding dose, directions, 
purpose, duration, technique), practical (cost, administration, 
side effects), and belief/efficacy (fear of long term effects, 
stigma, doubt benefit, low self-efficacy) barriers.  Pharmacists 
implemented patient-centered solutions to address specific 
problems.  For example, pharmacists provided patient 
education about the purpose of rescue and controller 
medications when a knowledge gap was identified pertaining 
to the need for two different types of inhalers.  In addition, 
participants were sent tailored (according to participants’ 
preferences and needs) educational materials via postal 
mail.
38-40
   
 
Because the target population participates in a federally-
funded prescription drug program, cost issues should rarely 
occur.  However, participants’ drug program eligibility can 
change during the study period.  Therefore, pharmacists 
referred participants to the MC Patient Assistance Center 
when cost issues were identified.  Pharmacists used 
motivational interviewing (MI) to address problems related to 
low efficacy or motivation.  MI is a theory-based skillful 
clinical method and style of counseling and psychotherapy 
designed for assessing patients’ source of motivation and 
assisting patients to commit to change.
41
  MI has been found 
to help patients overcome motivational barriers and adhere 
to prescribed regimens.
42
    
 
Inhaler technique is an important factor to address for 
management of asthma medication use.  We developed a 
series of questions to assess participants’ inhaler technique 
telephonically.  Pharmacists used these questions to evaluate 
whether participants need additional education regarding 
inhaler technique.  If problems with inhaler technique were 
identified, pharmacists provided verbal instruction on the 
telephone and also may have sent participants educational 
material via postal mail depending upon participants’ desires. 
 
Pharmacists have access to participants’ health and 
medication records through an electronic medical records 
system.  Pharmacists reviewed participants’ records and/or 
contacted their primary health care provider if they deemed 
it clinically necessary to help the participant resolve identified 
problems.  If severe asthma-related problems were identified, 
pharmacists referred participants to the appropriate health 
care provider which may include their primary care provider, 
specialty provider, or urgent care/emergency room services 
provider.    
 
Pharmacists electronically documented each encounter with 
intervention group participants via a MicroSoft Access 
database.  The database was constructed based upon the 
communication guide.  The database contains check-boxed 
standardized options as well as open-field options to allow 
pharmacists to include free text notes regarding their 
encounters with intervention group participants.  Pharmacists 
reviewed previous documentation before initiating 
subsequent contacts with the intervention group. 
 
Pharmacist Training and Skill Assessment 
Pharmacist training to provide the intervention was based 
upon self-efficacy theory.
43
  Bandura (1986) defines self-
efficacy as “people’s judgments of their capabilities to 
organize and execute courses of action required to attain 
designated types of performances” (p. 391).
44
  Bandura 
proposes that self-efficacy is an important function in human 
behavior because people’s beliefs in their personal efficacy 
influence decisions about which actions to pursue (Bandura, 
1986; Bandura, 1994).
44,45
 Stronger beliefs in one’s ability to 
perform a specific behavior lead to a greater likelihood of 
performing that specific behavior (Bandura, 1994).
45
  
 
The behavior of interest in this study is the study pharmacist’s 
use of the communication guide during consultations with 
intervention group participants.  Thus, we sought to 
strengthen study pharmacists’ self-efficacy regarding their 
ability to use the communication guide.  The intervention 
training encompassed the observation of role models, 
mastery experiences, and direct feedback; these components 
are hypothesized to enhance self-efficacy beliefs.
43
  The 
intervention training consisted of two 8-hour sessions.   
 
In the first session, a patient-provider communication expert 
educated study pharmacists about the components of the 
communication guide: RIM technique, IHS patient-counseling 
model, concordance, and MI.  The pharmacists also were 
shown mock encounters of a pharmacist using the 
communication guide during a patient consultation.  Next, 
the pharmacists practiced using the communication guide 
during role-playing exercises.  The patient-provider 
communication expert provided guidance and constructive 
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feedback regarding pharmacists’ role-playing performances.  
During the second session, an established asthma educator 
and researcher provided an overview of asthma 
management.  In order to ensure clinical consistency in 
intervention efforts, study pharmacists were evaluated and 
benchmarked through the National Asthma Educator 
Certification Board Exam.     
 
Process and Outcome Evaluation   
Both process and outcome evaluation are being conducted 
(Table 1).  A part of our process evaluation is to examine the 
pharmacists’ fidelity to the interaction protocol 
(communication guide).  Study pharmacists are evaluated 
during the implementation of the intervention by a health 
communication specialist.  The health communication 
specialist listens to the pharmacists during interactions with 
study participants.  Using the standardized counseling 
framework as a guide, the specialist reviews and makes 
comments about the study pharmacists’ adherence to the 
counseling protocol.  After the interaction with the study 
participant, the specialist and study pharmacist review the 
evaluation and deviations from the framework are discussed.  
In addition, the study team conducts weekly meetings to 
discuss issues that arise during the intervention period.  
Interviews with a random subset of intervention group 
participants also are conducted.  A research assistant uses a 
standardized interview guide to conduct confidential, one-on-
one interviews (via telephone) to explore facilitators and 
barriers associated with the intervention.  All interviews are 
audio-recorded.  Finally, enrollment status is being assessed 
to identify accrual and dropout rates and reasons for 
dropout. 
 
This study is also conducting outcome evaluation. Research 
outcomes include participants’ control of asthma, adherence 
to asthma medications, patient activation, and patient 
satisfaction.  These outcomes are assessed during the pre- 
and post-intervention telephone surveys.  The Asthma 
Control Test (ACT) is used to measure patients’ control of 
asthma.
46
  The ACT measures the level of impairment due to 
asthma over the past 30 days.  Adherence is measured by 
reviewing medication profile records for refill history and by 
self-report.  Self-reported adherence is assessed with Morisky 
Medication Adherence Scale (MMAS).
47
  Patient activation is 
measured with the Patient Activation Measure (PAM).
48
  We 
use a revised patient satisfaction scale to assess patients’ 
acceptance of the intervention.
49
 Table 2 displays ACT, 
MMAS, PAM, and patient satisfaction items. 
 
Participants’ health literacy also is assessed because of the 
potential influence on study outcomes.
50
  Health literacy is 
assessed with the Short Test of Functional Health Literacy in 
Adults (sTOFLA) during the post-intervention telephone 
survey to reduce respondent burden during the pre-
intervention survey phase.
51
  Prior to the post-intervention 
telephone survey, all participants are mailed a packet of 
materials including a letter and a sealed envelope (containing 
the sTOFLA).  The letter instructs the participant to keep the 
sealed envelope closed until the telephone interviewer 
informs them to open it.  During the post-intervention 
telephone survey call, the interviewer asks the participant to 
open the sealed envelope and complete the sTOFLA.  The 
interviewer asks the participant to read her/his responses 
and the interviewer records the participant’s answers.  The 
participant then is instructed to place the completed sTOFLA 
instrument in a self-addressed envelope and place the 
envelope in the mail.  The interviewer also asks the 
participant if they opened the envelope prior to the 
telephone call and if they had help completing the sTOFLA. 
 
Demographic and environmental characteristics and medical 
condition information also is collected.  Demographic data 
include age, gender, race/ethnicity, education, and income.  
We use items from the Centers for Disease Control and 
Prevention’s National Asthma Survey to assess participants’ 
environmental factors that may affect asthma.  Current 
smoking status, the number of self-reported asthma 
exacerbations experienced in the past 6 months that require 
urgent medical care and the number of asthma-related 
hospital admissions within the past six months also are 
gathered by self-report.
52
  The reliability and validity of self-
reported exacerbations and hospitalizations data will be 
assessed by comparisons with electronic health records. 
  
Analysis Plan  
Descriptive statistics (percentages, means, and standard 
deviations) will be reported for all baseline variables by 
assigned group, including patient satisfaction, asthma control, 
self-reported adherence, and patient activation.  Differences 
from baseline and month 5 for numeric variables will be 
compared by group.  These will be tested with either a 
Student's t-test or Wilcoxon signed rank test, against the null 
hypothesis that the difference of the mean/median is equal 
to zero.  The Wilcoxon test will be used if it is likely that the 
underlying distribution for a numerical variable is non-
normal.  Categorical variables will have the distribution from 
baseline compared to the distribution from month 5 by using 
a Chi-square test.  One-on-one interview data will be 
analyzed to uncover themes related to the facilitators and 
barriers associated with the intervention. 
 
Accrual and dropout rates will be calculated overall and by 
group.  Accrual rate will be calculated by average patients 
enrolled per week, and dropout rate will be determined by 
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the number of participants lost to follow up divided by total 
number of participants.  The means and standard deviations 
of the outcomes such as ACT, adherence measures, and PAM 
will be estimated.  These estimates will be used in calculating 
sample size and power for statistical tests to be performed in 
future large studies. 
 
Discussion 
This article describes the methodology used in one pilot study 
to help model how process and outcome evaluation can be 
integrated into preliminary pharmacy service delivery 
research involving 100 or fewer patients.  By including both 
process and summative data collection, even at the pilot 
study level, it is possible to evaluate the feasibility of the 
intervention and at the same time gain important clues to 
improve the field’s ability to address research challenges and 
intervention barriers, refine staff training, explore patient 
perspectives, and test measures’ power to provide 
preliminary patient outcome findings.  
 
Study resources and pharmacy site capacity influence the 
structure of extensive data collection.  In this example, a large 
regional health system provided an opportunity for a variety 
of process and summative data opportunities. As Table 1 
summarizes, qualitative (e.g., audiotape interview data) as 
well as quantitative data are collected to refine study 
methods and evaluate the impact of the intervention as well 
as contribute to future analyses of pharmacist and patient 
perceptions.  This information will guide the development of 
a larger study to examine the impact of this intervention on 
asthma patient outcomes. 
 
The collection of summative data for outcome evaluation is 
standard as it details the effectiveness of the intervention.  
However, process evaluation (i.e., formative evaluation, 
program monitoring, and implementation assessment) 
provides feedback for improving the intervention, helps to 
explain and interpret findings, and provides information to 
aid the replication of the intervention in alternative 
contexts.
53
  In this study, process evaluation allows for an 
examination of the research project processes and fidelity of 
the pharmacist service delivery to protocols.  A careful 
analysis of project activities can provide information about 
inefficiencies that can hinder the research efforts and allow 
the researchers an opportunity to immediately correct 
methodological issues or inform future studies.  Regarding 
the interpretation of findings, the documentation of 
participants’ experiences during the intervention helps 
explain how and why outcomes were or were not achieved.
53
  
Finally, gaining an understanding of how the program’s 
processes operate from multiple perspectives (e.g., providers’ 
and participants’) can be vital for the translation of the 
intervention into a larger trial or everyday practice.  For 
example, Sorensen et al found it necessary to facilitate 
effective collaboration between physicians and pharmacists 
in order to make the intervention translatable across a 
nationwide research effort.
54
    
 
Study barriers and limitations 
Investigators can be confronted with barriers that can impede 
the research enterprise when conducting practice-based 
intervention studies.  Such barriers include obtaining 1) “buy 
in” from the practice, supervisors and providers, and 2) 
provider participation.  In this study, we are overcoming 
these barriers by targeting a problem area that the practice 
itself selected (i.e., asthma care) and, perhaps the most 
pertinent key, fostering a collaborative culture that includes 
all stakeholders as members of the research team.  The 
collaborative culture entails involving pharmacists in every 
step of the research process, from conceptualization to 
implementation and evaluation.  For example, study 
pharmacists were involved with constructing the counseling 
framework and intervention procedures.  Study pharmacists 
participated in discussions about data collection measures 
and length of the pharmacist intervention study period.  The 
most frequently asked question was “how can we make this 
intervention feasible for you and your practice?”  This 
involvement has been invaluable to the success of the project 
and continued enthusiasm of participating pharmacists. 
 
In addition to potential barriers, there are potential 
limitations to this pilot study.  First, this study was not 
powered to detect effects of the intervention, and patients 
with poor asthma control were not targeted for recruitment. 
However, the purpose of this study was to conduct a pilot 
test.  Thus, we were primarily interested in the feasibility and 
acceptability of the intervention as well as facilitators and 
barriers to the implementation of the intervention. Pilot 
studies help to determine the plausibility of the intervention 
from the perspectives of those who are involved (patients, 
clinicians, etc). The study design outlines a strategy for 
piloting an intervention that can lead to a larger study aimed 
to more rigorously examine the effectiveness of the 
intervention (i.e., address issues of clustering by pharmacist 
and accounting for important covariates such as disease 
severity). Second, the consultation process outlined in the 
study protocol could be a weakness (e.g., time demands). 
From the participant’s perspective, the question was whether 
the intervention may take too long and thus decrease their 
willingness to continue participation. From the pharmacist’s 
perspective, the question was whether the consultation 
process may be impractical and lead to deviations in the 
protocol.  Our evaluation strategies should illuminate issues 
regarding whether the counseling framework is burdensome. 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2011, Vol. 2, No. 3, Article 49                         INNOVATIONS in pharmacy   7 
 
For example, we may find that 1) the percentage of 
participant drop-out is higher in the intervention groups, 2) 
participants reported this as a barrier during one-on-one 
interviews, or 3) study pharmacists have poor protocol 
fidelity. 
 
Summary 
In conclusion, the primary study objective is to conduct an 
initial assessment of a pharmacy-based intervention.  We 
present a methodological design that uses qualitative and 
quantitative approaches to implement and evaluate a service 
delivery model.  Results will provide evidence regarding the 
plausibility and quality of carrying out the study and service 
delivery from the multiple perspectives of participants and 
clinicians.   
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Table 1. Summary of Evaluation Tools 
Evaluation Data Collection Purpose Measures 
Process Direct observation Fidelity to protocol Review 
 Interview (pharmacists) Identify issues affecting implementation Interview questions 
 Telephone Interview 
(participants) 
Identify barriers & facilitators to participation Interview questions 
Outcome Pre-survey Asthma Control, Adherence, Patient 
Activation, Patient Satisfaction, 
Demographics 
Asthma Control Test, Morisky 
Medication Adherence Scale, Patient 
Activation Measure, Patient 
Satisfaction 
 Post-survey Asthma Control, Adherence, Patient 
Activation, Patient Satisfaction, Health 
Literacy, Environmental factors 
Asthma Control Test, Morisky 
Medication Adherence Scale, Patient 
Activation Measure, Patient 
Satisfaction, sTOFLA, National 
Asthma Survey 
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Table 2. Asthma Control Test
46
, Morisky Medication Adherence Scale
47
, Patient Activation Measure
48
, and Patient Satisfaction tems
49
 
 
Asthma Control Test 
In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home? 
During the past 4 weeks, how often have you had shortness of breath? 
During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness, or pain) 
wake you up at night or earlier than usual in the morning? 
During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol)? 
How would you rate your asthma control during the past 4 weeks? 
 
Morisky Medication Adherence Scale 
Do you sometimes forget to take your asthma medication? 
Over the past 2 weeks, were there any days when you did not take your asthma medicine? 
Have you ever cut back or stopped taking your asthma medication without telling your doctor because you felt worse when you took 
it? 
When you travel or leave home, do you sometimes forget to bring along your asthma medications? 
Did you take your asthma medicine yesterday? 
When you feel like your asthma is under control, do you sometimes stop taking your medicine? 
Taking medication everyday is a real inconvenience for some people. Do you ever feel hassled about sticking to your asthma 
treatment plan? 
How often do you have difficulty remembering to take all your asthma medication? 
 
Patient Activation Measure 
When all is said and done, I am the person who is responsible for managing my health condition. 
Taking an active role in my own health care is the most important factor in determining my health and ability to function. 
I am confident that I can take actions that will help prevent or minimize some symptoms or problems associated with my health 
condition. 
I know what each of my prescribed medications do. 
I am confident that I can tell when I need to go get medical care and when I can handle a health problem myself. 
I am confident I can tell my health care provider concerns I have even when he or she does not ask. 
I am confident that I can follow through on medical treatments I need to do at home. 
I understand the nature and causes of my health condition(s). 
I know the different medical treatment options available for my health condition. 
I have been able to maintain the lifestyle changes for my health that I have made. 
I know how to prevent further problems with my health condition. 
I am confident I can figure out solutions when new situations or problems arise with my health condition. 
I am confident that I can maintain lifestyle changes like diet and exercise even during times of stress. 
 
Patient Satisfaction 
How would you rate the pharmacist’s ability to help you manage your asthma therapy? 
How would you rate the pharmacist’s ability to help you prevent problems with your asthma? 
Rate the overall care you received from your pharmacists. 
 
